Our 2018 Agenda

Edit
Time	Description
2:00 – 2:45pm	Registration
2:45 – 3:00pm	Welcome and Introductions
3:00 – 3:45pm	Keynote: *Opportunities in Integrating Biologic Drug Structure and In Vivo* PTM Data into Clinical Program Design and Analysis—An FDA Perspective Steve Kozlowski, MD, Director, Office of Biotechnology Products, US Food and Drug Administration**
3:45 – 4:30pm	Keynote: *Opportunities in Integrating Biologic Drug Structure and In Vivo* PTM Data into Clinical Program Design and Analysis—A Pharma Perspective Wassim Nashabeh, PhD, Vice President, Regulatory Policy and International Operations, Roche Pharmaceutical Group**
4:30 – 4:45pm	Break
4:45 – 5:45pm	Panel Discussion With Keynote Speakers Patrick Swann, PhD, Vice President, Quality Science and Technology, Amgen; Former Vice President, CMC Regulatory Affairs, Biogen and Deputy Director, Division of Monoclonal Antibodies, US Food and Drug Administration Katy Stein, PhD, Principal, Kathryn Stein Consulting; Former Director, Division of Monoclonal Antibodies, US Food and Drug Administration and Senior Vice President, Product Development and Regulatory Affairs, Macrogenics Pamela M. Klein, MD, Principal, PMK BioResearch; Former Chief Medical Officer, Intellikine (acquired by Millennium/Takeda) and Vice President, Development, Genentech
5:45 – 6:30pm	Closing Cocktail Reception